pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease
Mokrowiecka, A.; Gasiorowska, A.; Malecka-Panas, E.
Hepato-Gastroenterology 54(77): 1443-1448
2007
ISSN/ISBN: 0172-6390 PMID: 17708273 Document Number: 2951
Background/Aims: The measurement of perinuclear antineutrophil cytoplasmic (pANCA) and antiSaccharomyces cerevisiae antibodies (ASCA) has recently been suggested as a valuable and nonirivasive diagnostic approach in the differentiation of ulcerative colitis (UC), Crohn's disease (CD) and indeterminate colitis (IC).The aim of the study was to determine the prevalence of pANCA and ASCA in patients with inflammatory bowel disease (IBD) subgroups of different clinical course and to assess their accuracy in differential diagnosis.Methodology: The study was performed in 109 patients: 50 patients with UC, 17 with CD, 18 with IC and 24 non-IBD controls. Antibodies status has been measured with ELISA, using commercial antibody panel by MedTek kits, confirmed by IIF technique using Euroimmun panels.Results: Sensitivity and specificity of pANCA+/ASCA- pattern for UC diagnosis was 36% and 98%; pANCA-/ASCA+ for CD: 35% and 88%, pANCA/ASCA- for IC: 72% and 63%, respectively.In addition the significant positive correlation between antibodies profiles: pANCA+/ASCA- and active disease; pANCA-/ASCA+ and number of operations, as well as the negative correlation between pANCA-/ASCA- and patient's age has been found.Conclusions: Our study lends further support to the opinions that serologic assessment identifies a large subset of different subtypes of IBD patients.
Document emailed within 1 workday
